The role of the National Cancer Institute in drug development.
作者信息
Doroshow James
机构信息
Division of Cancer Treatment and Diagnosis, National Cancer Institute, MD, USA.
出版信息
Clin Adv Hematol Oncol. 2005 Apr;3(4):257-8.
PMID:16166997
Abstract
摘要
相似文献
1
The role of the National Cancer Institute in drug development.
Clin Adv Hematol Oncol. 2005 Apr;3(4):257-8.
2
Japan works to shorten "drug lag," boost trials of new drugs.
J Natl Cancer Inst. 2010 Feb 3;102(3):148-51. doi: 10.1093/jnci/djq017. Epub 2010 Jan 27.
3
Slow start to phase 0 as researchers debate value.
J Natl Cancer Inst. 2006 Jun 21;98(12):804-6. doi: 10.1093/jnci/djj249.
4
Can single-patient investigational new drug studies hurry slow trains to the fast track?
Drug Discov Today. 2006 Mar;11(5-6):185-6. doi: 10.1016/S1359-6446(05)03707-4.
5
[Antitumor drug screening at the National Cancer Institute, U.S.A].
Gan To Kagaku Ryoho. 1987 Oct;14(10):2809-15.
6
Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
Semin Oncol. 1997 Apr;24(2):219-40.
7
Developing new agents for the treatment of childhood cancer.
Curr Opin Investig Drugs. 2005 Dec;6(12):1215-27.
8
Adaptive trials receive boost.
Nat Rev Drug Discov. 2010 May;9(5):345-8. doi: 10.1038/nrd3174. Epub 2010 Apr 23.
9
Learning from exceptional drug responders.
Nat Rev Drug Discov. 2014 Jun;13(6):401-2. doi: 10.1038/nrd4338.
10
Clinical development of anticancer agents--a National Cancer Institute perspective.
Cancer Treat Rep. 1984 Jan;68(1):77-85.
Zotero 插件